Filing Details
- Accession Number:
- 0001564590-22-026039
- Form Type:
- 13D Filing
- Publication Date:
- 2022-07-19 20:00:00
- Filed By:
- Griffiths Richard Ian
- Company:
- Silence Therapeutics Plc
- Filing Date:
- 2022-07-20
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Richard Ian Griffiths | 25,469,271 | 0 | 25,469,271 | 0 | 25,469,271 | 28.4% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Silence Therapeutics plc
(Name of Issuer)
Ordinary Shares, nominal value £0.05 per share
(Title of Class of Securities)
G8128Y157
(CUSIP Number)
Richard Griffiths
Floor 1 Liberation Station
Esplanade, St Helier, Jersey, JE2 3AS
Tel: +44 1534 719761
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
July 19, 2022
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13D
CUSIP No. G8128Y157 |
| Page 2 of 4 |
(1) | Names of reporting persons Richard Ian Griffiths | ||
(2) | Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐ | ||
(3) | SEC use only
| ||
(4) | Source of funds (see instructions) PF | ||
(5) | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||
(6) | Citizenship or place of organization Jersey, Channel Islands | ||
Number of | (7) | Sole voting power 25,469,271* | |
shares beneficially owned by | (8) | Shared voting power 0 | |
each reporting person | (9) | Sole dispositive power 25,469,271* | |
with: | (10) | Shared dispositive power 0 | |
(11) | Aggregate amount beneficially owned by each reporting person 25,469,271* | ||
(12) | Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ☐ | ||
(13) | Percent of class represented by amount in Row (11) 28.4%** | ||
(14) | Type of reporting person (see instructions) IN |
* Mr. Griffiths beneficially owns an aggregate of 25,469,271 ordinary shares, nominal value £0.05 per share (the “Shares”), of Silence Therapeutics plc (the “Company”), consisting of 8,489,757 American Depositary Shares (“ADSs”), each of which represents, and at the holder’s option is convertible into, three Shares. Mr. Griffiths holds certain ADSs through the following entities of which he is a director and the controlling shareholder: (i) 1,651,207 ADSs held through Ora Ventures Limited; (ii) 620,238 ADSs held through Sarossa Plc; (iii) 4,628 ADSs held through Serendipity Capital Limited; (iv) 280,717 ADSs held through Cream Capital Limited; (v) 1,355,133 ADSs held through Blake Holdings Limited; and (vi) 4,577,834 ADSs held personally.
** The aggregate percentage of Shares reported owned by Mr. Griffiths is based upon 89,789,713 Shares issued and outstanding as of March 31, 2022, as disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on May 16, 2022.
Explanatory Note
This Amendment No. 1 (this “Amendment”) amends and supplements the Schedule 13D (the “Schedule 13D”) filed by Richard Ian Griffiths (the “Reporting Person”) on June 15, 2022. Except as specifically amended and supplemented by this Amendment, all previous Items are unchanged. Capitalized terms used but not defined in this Amendment have the meanings given to such terms in the Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 is hereby amended and supplemented as follows:
A total of approximately $4.2 million was paid to acquire Shares between June 10, 2022 and July 19, 2022.
Item 5. Interest in Securities of the Company
Item 5 is hereby amended and supplemented as follows:
(a)-(b). Rows (7) through (13) of the cover page of this Schedule 13D are hereby incorporated by reference.
(c). During the past 60 days, the Reporting Person effected the following transactions:
Date | Type of Transaction | Entity/Individual | Number of Shares | Price per Share |
06/08/2022 | Open Market Purchase | Blake Holdings Limited | 1,050,000 | $7.50 |
06/08/2022 | Open Market Purchase | Richard Griffiths | 200,000 | $7.50 |
06/09/2022 | Open Market Purchase | Richard Griffiths | 9,726 | $8.00 |
06/17/2022 | Open Market Purchase | Blake Holdings Limited | 80,000 | $8.00 |
06/22/2022 | Open Market Purchase | Richard Griffiths | 799 | $9.78 |
06/23/2022 | Open Market Purchase | Richard Griffiths | 4,000 | $12.03 |
06/24/2022 | Open Market Purchase | Richard Griffiths | 14,000 | $11.90 |
06/27/2022 | Open Market Purchase | Richard Griffiths | 10,000 | $11.78 |
06/28/2022 | Open Market Purchase | Blake Holdings Limited | 12,000 | $12.42 |
06/29/2022 | Open Market Purchase | Blake Holdings Limited | 11,518 | $11.43 |
06/30/2022 | Open Market Purchase | Blake Holdings Limited | 10,000 | $11.95 |
07/01/2022 | Open Market Purchase | Blake Holdings Limited | 17,000 | $11.28 |
07/07/2022 | Open Market Purchase | Blake Holdings Limited | 19,000 | $11.01 |
07/05/2022 | Open Market Purchase | Blake Holdings Limited | 20,000 | $11.02 |
07/07/2022 | Open Market Purchase | Blake Holdings Limited | 25,000 | $10.95 |
07/08/2022 | Open Market Purchase | Blake Holdings Limited | 32,000 | $10.97 |
07/11/2022 | Open Market Purchase | Blake Holdings Limited | 37,000 | $11.21 |
07/13/2022 | Open Market Purchase | Richard Griffiths | 51,922 | $10.79 |
07/14/2022 | Open Market Purchase | Richard Griffiths | 10,000 | $11.89 |
07/14/2022 | Open Market Purchase | Blake Holdings Limited | 14,615 | $11.89 |
07/15/2022 | Open Market Purchase | Blake Holdings Limited | 6,000 | $11.47 |
07/18/2022 | Open Market Purchase | Blake Holdings Limited | 11,000 | $11.38 |
07/19/2022 | Open Market Purchase | Blake Holdings Limited | 10,000 | $10.88 |
(d). To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.
(e). Not applicable.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: July 20, 2022 | /s/ Richard Griffiths |
| Richard Griffiths |